"Cladribine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
| Descriptor ID |
D017338
|
| MeSH Number(s) |
D03.633.100.759.590.138.300.200 D03.633.100.759.590.138.325.075 D13.570.230.229.075 D13.570.583.138.300.200 D13.570.583.138.325.075 D13.570.800.096.300.200
|
| Concept/Terms |
Cladribine- Cladribine
- 2-Chlorodeoxyadenosine
- 2-Chloro-2'-deoxyadenosine
- 2'-Deoxy-2-chloroadenosine
|
Below are MeSH descriptors whose meaning is more general than "Cladribine".
Below are MeSH descriptors whose meaning is more specific than "Cladribine".
This graph shows the total number of publications written about "Cladribine" by people in this website by year, and whether "Cladribine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2008 | 1 | 2 | 3 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cladribine" by people in Profiles.
-
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
-
Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. Haematologica. 2020 08; 105(8):e404-e407.
-
Patchy colitis and interstitial lung disease. Gastroenterology. 2015 Jan; 148(1):26-7.
-
RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics. 2013 Sep; 14(12):1449-66.
-
Fifty years of hairy cell leukemia treatments. Leuk Lymphoma. 2011 Jun; 52 Suppl 2:3-5.
-
Immune hemolytic anemia--selected topics. Hematology Am Soc Hematol Educ Program. 2009; 80-6.
-
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology. 2008 Jul 08; 71(2):136-44.
-
Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Leuk Res. 2008 Dec; 32(12):1830-6.
-
Hairy cell leukemia: treatment successes in the past 25 years. J Clin Oncol. 2008 Jun 01; 26(16):2607-9.
-
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases. Cancer Chemother Pharmacol. 2004 Dec; 54(6):553-61.